{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:31:23Z","timestamp":1785259883117,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.hoc.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T08:25:24Z","timestamp":1584519924000},"page":"523-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.1016","volume":"34","author":[{"given":"Kana","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.01.003_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/modpathol.2015.145","article-title":"Neoplasms derived from plasmacytoid dendritic cells","volume":"29","author":"Facchetti","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hoc.2020.01.003_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.09.006","article-title":"Genomic aberrations involving 12p\/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events","volume":"73","author":"Tang","year":"2018","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.hoc.2020.01.003_bib4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/leu.2017.101","article-title":"Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm","volume":"31","author":"Suzuki","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2020.01.003_bib5","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","article-title":"Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response","volume":"32","author":"Sakamoto","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.01.003_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2018.01.013","article-title":"8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms","volume":"66","author":"Boddu","year":"2018","journal-title":"Leuk Res"},{"issue":"15","key":"10.1016\/j.hoc.2020.01.003_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2020.01.003_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/modpathol.3800742","article-title":"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature","volume":"20","author":"Reichard","year":"2007","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00000478-199902000-00001","article-title":"CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC)","volume":"23","author":"Petrella","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1309\/UUXV-YRL8-GXP7-HR4H","article-title":"Blastic natural killer cell lymphoma\/leukemia: a report of seven cases","volume":"117","author":"Bayerl","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2020.01.003_bib11","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","article-title":"CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique","volume":"99","author":"Leroux","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.01.003_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13039-016-0232-1","article-title":"Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review","volume":"9","author":"Tang","year":"2016","journal-title":"Mol Cytogenet"},{"issue":"3","key":"10.1016\/j.hoc.2020.01.003_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1523-1747.2003.12406.x","article-title":"Genomic alterations in blastic natural killer\/extranodal natural killer-like T\u00a0cell lymphoma with cutaneous involvement","volume":"121","author":"Mao","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2020.01.003_bib14","first-page":"317","article-title":"CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells","volume":"14","author":"Hallermann","year":"2004","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2020.01.003_bib15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/DAD.0b013e31824d689c","article-title":"Alpha-interferon secreting blastic plasmacytoid dendritic cells neoplasm: a case report with histological, molecular genetics and long-term tumor cells culture studies","volume":"34","author":"Petrella","year":"2012","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.hoc.2020.01.003_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1684\/ejd.2012.1663","article-title":"Loss of genomic DNA copy numbers in the p18, p16, p27 and RB loci in blastic plasmacytoid dendritic cell neoplasm","volume":"22","author":"Oiso","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib17","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2006-04-018143","article-title":"Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities","volume":"109","author":"Dijkman","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/leu.2008.359","article-title":"Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1\/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease","volume":"23","author":"Jardin","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/jid.2009.369","article-title":"Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms","volume":"130","author":"Wiesner","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"17","key":"10.1016\/j.hoc.2020.01.003_bib20","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","article-title":"Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion","volume":"118","author":"Lucioni","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.01.003_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08556.x","article-title":"TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm","volume":"153","author":"Jardin","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cell.2006.10.003","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.hoc.2020.01.003_bib23","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.18632\/oncotarget.2223","article-title":"Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm","volume":"5","author":"Stenzinger","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2018.202093","article-title":"Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target","volume":"104","author":"Sapienza","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.hoc.2020.01.003_bib26","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2017.04.005","article-title":"ETV6 in hematopoiesis and leukemia predisposition","volume":"54","author":"Hock","year":"2017","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2020.01.003_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-018-0120-5","article-title":"Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.hoc.2020.01.003_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2013.283","article-title":"Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm","volume":"28","author":"Menezes","year":"2014","journal-title":"Leukemia"},{"issue":"7\u20138","key":"10.1016\/j.hoc.2020.01.003_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cancergen.2013.07.002","article-title":"Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms","volume":"206","author":"Fu","year":"2013","journal-title":"Cancer Genet"},{"issue":"24","key":"10.1016\/j.hoc.2020.01.003_bib32","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2015-09-671040","article-title":"Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms","volume":"127","author":"Emadali","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2020.01.003_bib33","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1016\/j.febslet.2010.09.042","article-title":"Ikaros in immune receptor signaling, lymphocyte differentiation, and function","volume":"584","author":"Merkenschlager","year":"2010","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41467-018-02977-8","article-title":"Ikaros family zinc finger 1 regulates dendritic cell development and function in humans","volume":"9","author":"Cytlak","year":"2018","journal-title":"Nat Commun"},{"issue":"7191","key":"10.1016\/j.hoc.2020.01.003_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2020.01.003_bib36","doi-asserted-by":"crossref","first-page":"e1007485","DOI":"10.1371\/journal.pgen.1007485","article-title":"Ikaros cooperates with Notch activation and antagonizes TGFbeta signaling to promote pDC development","volume":"14","author":"Mastio","year":"2018","journal-title":"PLoS Genet"},{"key":"10.1016\/j.hoc.2020.01.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/757534","article-title":"Mammalian MYC proteins and cancer","volume":"2014","author":"Tansey","year":"2014","journal-title":"New J Sci"},{"issue":"11","key":"10.1016\/j.hoc.2020.01.003_bib38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cancergen.2015.06.004","article-title":"Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation","volume":"208","author":"Ohanian","year":"2015","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jmoldx.2018.10.005","article-title":"t(3;8)(q26.2;q24) often leads to MECOM\/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and\/or disease progression","volume":"21","author":"Tang","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"issue":"7","key":"10.1016\/j.hoc.2020.01.003_bib40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0145-2126(01)00198-9","article-title":"Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases","volume":"26","author":"Momoi","year":"2002","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1532\/IJH97.04116","article-title":"A\u00a0novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma","volume":"81","author":"Maeda","year":"2005","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3960\/jslrt.52.107","article-title":"Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia","volume":"52","author":"Takiuchi","year":"2012","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.hoc.2020.01.003_bib43","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1038\/bcj.2015.26","article-title":"Identification of SUPT3H as a novel 8q24\/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation","volume":"5","author":"Nakamura","year":"2015","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.hoc.2020.01.003_bib44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00277-017-2947-4","volume":"96","author":"Tzankov","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.01.003_bib45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/his.13668","article-title":"An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality","volume":"73","author":"Sumarriva Lezama","year":"2018","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.hoc.2020.01.003_bib46","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.01.003_bib47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.15128","article-title":"Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations","volume":"181","author":"Kurt","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.01.003_bib48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A\u00a0druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib49","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41467-019-09710-z","article-title":"Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm","volume":"10","author":"Kubota","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib50","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/cancers6042049","article-title":"Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis","volume":"6","author":"George","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-15-0859","article-title":"Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma","volume":"6","author":"Brayer","year":"2016","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.hoc.2020.01.003_bib52","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1073\/pnas.1300252110","article-title":"Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1","volume":"110","author":"Ramkissoon","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.22119","article-title":"CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm","volume":"53","author":"Tokuda","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.leukres.2011.07.029","article-title":"The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement","volume":"36","author":"Toya","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2020.01.003_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.humpath.2005.10.005","article-title":"CD4+\/CD56+ hematologic malignancy with rearranged MLL gene","volume":"37","author":"Leung","year":"2006","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib56","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno","year":"2004","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2020.01.003_bib57","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cancergen.2015.04.011","article-title":"KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm","volume":"208","author":"Yang","year":"2015","journal-title":"Cancer Genet"},{"issue":"4","key":"10.1016\/j.hoc.2020.01.003_bib58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3892\/etm.2015.2236","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: a case report","volume":"9","author":"Gao","year":"2015","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.01.003_bib59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jclinpath-2013-201792","article-title":"Blastic plasmacytoid dendritic cell neoplasm with EWSR1 gene rearrangement","volume":"67","author":"Cao","year":"2014","journal-title":"J\u00a0Clin Pathol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:08Z","timestamp":1760184788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0889858820300149"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.01.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}